Semaglutide vs Tirzepatide: A Head-to-Head Comparison of the Two Leading GLP-1 Medications

Semaglutide and tirzepatide represent two generations of incretin-based therapies. Understanding their distinct mechanisms helps explain the differences in clinical outcomes between these medications.

Semaglutide is a pure GLP-1 receptor agonist. It binds exclusively to GLP-1 receptors in the brain, pancreas, and gastrointestinal tract. By mimicking the natural gut hormone GLP-1, semaglutide slows gastric emptying, enhances glucose-dependent insulin secretion, suppresses glucagon release, and reduces appetite by acting on hypothalamic hunger centers. Semaglutide is manufactured by Novo Nordisk and is available as Ozempic (type 2 diabetes, up to 2 mg weekly), Wegovy (weight management, 2.4 mg weekly), and Rybelsus (oral tablet for diabetes).

Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first in its class. In addition to all the GLP-1 effects described above, tirzepatide simultaneously activates GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP signaling enhances insulin sensitivity in adipose tissue, promotes efficient fat metabolism, and may provide additional appetite suppression through complementary brain pathways. This dual mechanism is believed to produce the superior weight loss and metabolic outcomes observed in tirzepatide clinical trials. Tirzepatide is manufactured by Eli Lilly as Mounjaro (type 2 diabetes) and Zepbound (weight management).

The most direct comparison of semaglutide and tirzepatide comes from their respective Phase 3 clinical trial programs — STEP (semaglutide) and SURMOUNT (tirzepatide). While these were not head-to-head trials, their designs were similar enough to allow meaningful cross-trial comparisons.

In the STEP 1 trial, semaglutide 2.4 mg produced an average weight loss of 14.9% of body weight over 68 weeks in adults with obesity or overweight. The placebo group lost 2.4%. Among participants on semaglutide, 32% achieved weight loss of 20% or more.

In the SURMOUNT-1 trial, tirzepatide produced dose-dependent weight loss over 72 weeks: 15.0% at 5 mg, 19.5% at 10 mg, and 22.5% at 15 mg. The placebo group lost 3.1%. At the highest dose, 36% of participants lost at least 25% of their body weight, and 63% lost at least 20%.

The SURPASS-2 trial provided a direct head-to-head comparison in type 2 diabetes, pitting tirzepatide against semaglutide 1 mg (the Ozempic dose, not the higher Wegovy dose). Tirzepatide at all doses (5 mg, 10 mg, 15 mg) produced statistically superior A1C reductions and weight loss compared to semaglutide 1 mg. At 15 mg, tirzepatide achieved 2.46% A1C reduction vs. 1.86% for semaglutide, and 12.4 kg greater weight loss.

Both semaglutide and tirzepatide share a similar gastrointestinal side effect profile, which is characteristic of the GLP-1 receptor agonist class. However, there are subtle differences in incidence rates and patterns worth noting.

Nausea is the most common side effect for both medications. In STEP trials, nausea occurred in approximately 44% of semaglutide patients (vs. 17% placebo), while in SURMOUNT trials, nausea occurred in 24-33% of tirzepatide patients (depending on dose). Importantly, nausea is typically transient for both medications, peaking during dose escalation and resolving within weeks for most patients.

Diarrhea rates were comparable: approximately 30% for semaglutide 2.4 mg and 17-25% for tirzepatide across doses. Constipation affected about 24% of semaglutide patients and 12-17% of tirzepatide patients. Vomiting occurred in roughly 24% of semaglutide users and 6-12% of tirzepatide users. These comparisons suggest tirzepatide may have a modestly more favorable GI tolerability profile, though differences in trial design, population, and reporting make direct conclusions difficult.

Discontinuation rates due to adverse events were 7% for semaglutide 2.4 mg in STEP 1 and 4.3-7.1% for tirzepatide across doses in SURMOUNT-1. Both medications carry the same class warnings regarding medullary thyroid carcinoma, pancreatitis, and gallbladder disease. Neither medication is associated with clinically meaningful hypoglycemia when used without insulin or sulfonylureas.

Both medications offer significant metabolic benefits beyond weight loss, though semaglutide currently has a larger body of cardiovascular outcomes data.

Semaglutide received a landmark expanded FDA indication in March 2024 based on the SELECT trial, which demonstrated a 20% reduction in major adverse cardiovascular events (MACE) — defined as cardiovascular death, nonfatal heart attack, or nonfatal stroke — in overweight or obese adults with established cardiovascular disease but without diabetes. This was the first anti-obesity medication to demonstrate cardiovascular risk reduction in a dedicated outcomes trial.

Tirzepatide's cardiovascular outcomes trial, SURPASS-CVOT, is ongoing and expected to report results. Preliminary data from existing trials show favorable cardiovascular markers: tirzepatide significantly reduces blood pressure (systolic BP dropped 6-9 mmHg in SURMOUNT-1), improves lipid profiles (reductions in triglycerides of 19-25%), and reduces inflammatory markers like C-reactive protein.

Both medications improve insulin sensitivity and reduce liver fat. In the SYNERGY-NASH trial, tirzepatide demonstrated resolution of metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) in 44-62% of patients at 52 weeks, suggesting potential for addressing fatty liver disease. Semaglutide showed similar liver benefits in the STEP-HFpEF trial, which also demonstrated improved heart failure symptoms in obese patients with heart failure with preserved ejection fraction.

Cost is a practical factor that influences medication choice for many patients. Brand-name pricing for both medications remains high, though insurance coverage and alternative access pathways can significantly reduce out-of-pocket expenses.

Wegovy (semaglutide 2.4 mg for weight loss) has a list price of approximately $1,350 per month. Ozempic (semaglutide for diabetes) costs around $900-$1,000 per month. Zepbound (tirzepatide for weight loss) is priced at approximately $1,060 per month, and Mounjaro (tirzepatide for diabetes) is around $1,023 per month. Without insurance, these costs present a significant barrier for many patients.

Compounded versions of both medications are available through licensed pharmacies at substantially lower prices. Compounded semaglutide typically costs $250-$400 per month, and compounded tirzepatide ranges from $300-$500 per month.

At Weight Method, we offer both medications at accessible price points: semaglutide at $297 per month and tirzepatide at $349 per month. Both subscriptions include the medication, initial medical evaluation, dosing guidance, and ongoing clinical support. Our clinicians help determine which medication is best suited to your metabolic profile, weight loss goals, and health history — because the right medication depends on individual factors, not just trial averages.